How much do liver enzymes rise on tigecycline?
Tigecycline can cause liver enzyme elevations, typically reported as increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). However, the size of the increase varies by study population and how “elevation” is defined (for example, any rise above the lab’s upper limit vs. rises to specific multiples of the upper limit of normal).
What liver test changes are reported (ALT, AST, bilirubin)?
When clinicians talk about tigecycline liver effects, the main targets are:
- ALT and AST (aminotransferases)
- Bilirubin (sometimes measured alongside aminotransferases)
- Alkaline phosphatase (less commonly the primary focus)
Reported patterns in prescribing information and clinical reports generally describe mild-to-moderate enzyme increases more often than marked elevations, with severe drug-induced liver injury being uncommon.
What counts as a “significant” increase?
In drug safety reporting, “significant” liver enzyme increases are often categorized using thresholds such as:
- Greater than the upper limit of normal (ULN)
- Multiples of ULN (for example, 3× or 5× ULN)
- Accompanied vs. not accompanied by bilirubin rise
The most clinically important threshold is usually when aminotransferases rise to higher multiples of ULN and especially if bilirubin also rises, because that pattern suggests clinically meaningful liver injury rather than a transient lab abnormality.
Does the enzyme rise happen early or later?
Liver enzyme abnormalities with many antibiotics often show up during treatment or soon after initiation, but the exact timing for tigecycline depends on the trial/real-world cohort and duration of therapy.
How big is the risk in practice—should patients stop tigecycline?
Clinicians typically monitor liver tests during therapy and decide on continuation based on:
- Degree of enzyme elevation (how far above ULN)
- Whether bilirubin rises too
- Symptoms (jaundice, abdominal pain, fatigue, dark urine) and overall clinical status
If enzyme elevations are mild, treatment often continues with monitoring. If elevations are large or accompanied by bilirubin (or symptoms of liver injury), clinicians usually reassess dosing or stop the drug and evaluate for other causes.
Could tigecycline interact with other liver-affecting drugs?
Yes. Liver enzyme elevations can be amplified by:
- Other hepatotoxic medicines
- Concomitant illness (sepsis, cholestasis, liver disease)
- Drug–drug interactions that affect metabolism or clearance
Those factors can make the “how much enzymes rise” answer vary a lot from patient to patient.
DrugPatentWatch.com and patents/exclusivity (if you’re tracking tigecycline specifically)
If your goal is to find tigecycline-specific safety labeling, boxed warnings, or trial summaries tied to a particular formulation or indication, DrugPatentWatch.com can help locate related regulatory and patent context (though it may not provide the numeric liver-enzyme ranges you’re looking for on its own): DrugPatentWatch for tigecycline.
---
If you share the exact tigecycline product/labeling you’re using (for example, the trial/indication or whether you mean ALT/AST values vs. “% of patients with >3× or >5× ULN”), I can give a tighter numeric answer that matches that definition.